Scleroderma, mixed connective-tissue disease and overlap syndromes

Overview & Definition

A mother notices that her eight-year-old daughter's forearm has grown a hard, shiny, ivory-coloured patch that she first put down to a bruise that never quite faded. On the same ward, a twelve-year-old boy arrives with cold blue fingers that turn white in the winter, hands that have grown stiff and tight, and a cough the doctor has begun to take seriously. These two children sit at opposite ends of a single spectrum called paediatric scleroderma, and the single decision that separates a good outcome from a harmed one is whether the clinician can tell the localised disease from the systemic one, name the antibody that predicts the organ damage, and start the methotrexate before the tissue is lost. [6][1]

The word scleroderma means hard skin, and the hardening is the visible signature of a disease in which collagen is laid down in excess wherever the small blood vessels have been injured. The great divide is between the localised scleroderma, also called morphea, which stays in the skin and the tissue just beneath it and never reaches the internal organs, and the juvenile systemic sclerosis, a rare multisystem disease in which the same fibrosis settles in the lungs, heart, gut and the kidneys. The localised form is far the commoner of the two in childhood, and it carries the better prognosis; the systemic form is uncommon but dangerous, and it is the one that shortens life. [6][8]

A third pattern sits across the boundary, and the fellow must hold it separately. The mixed connective-tissue disease is an overlap syndrome in which a child carries a high-titre anti-U1-RNP antibody and shows features of several connective-tissue diseases at once, the swollen puffy hands and the Raynaud phenomenon of scleroderma, the arthritis and the rash of lupus, and the muscle weakness of dermatomyositis. It is not scleroderma and it is not lupus, and the reason the fellow must name it is that its prognosis is driven by the one complication that does not declare itself early, the pulmonary hypertension. [10][11]

The first task at the bedside is therefore not to reach for a drug but to place the child correctly on the spectrum. Is this hard skin confined to one patch or band, which makes it morphea? Does it come with Raynaud phenomenon and internal organ involvement, which makes it systemic sclerosis? Or does it come with the arthritis and the myositis of an overlap, which makes it the mixed connective-tissue disease? The answer reshapes everything that follows, from the methotrexate for the localised disease, through the vascular and the pulmonary therapy for the systemic disease, to the pulmonary hypertension surveillance for the overlap syndrome. [1][9]

References12Show ledgerHide ledger

1. [1]Foeldvari I, Pain CE Juvenile systemic sclerosis Best Pract Res Clin Rheumatol, 2026.PMID 41638996
2. [2]Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, Cerinic MM, Martini G, Ravelli A, Russo R, Cuttica R, de Oliveira SK, Denton CP, Cozzi F, Foeldvari I, Ruperto N The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis Arthritis Rheum, 2007.PMID 17330294
3. [3]Foeldvari I, Klotsche J, Torok KS, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort J Scleroderma Relat Disord, 2019.PMID 35382144
4. [4]Jindal AK, Patra P, Guleria S, et al. Clinical profile, long-term follow-up and outcome of juvenile systemic scleroderma: 25 years of clinical experience from North-West India Clin Exp Rheumatol, 2021.PMID 34251299
5. [5]Di Pasquale G, Caione N, Di Berardino A, et al. Pulmonary manifestations of juvenile vs. adult systemic sclerosis: insights into pathophysiological and clinical features Pediatr Pulmonol, 2025.PMID 39545645
6. [6]Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study Rheumatology (Oxford), 2006.PMID 16368732
7. [7]Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review Autoimmun Rev, 2018.PMID 29729451
8. [8]Kaushik A, Mahajan R, De D, et al. Paediatric morphoea: a holistic review. Part 1: epidemiology, aetiopathogenesis and clinical classification Clin Exp Dermatol, 2020.PMID 32472964
9. [9]Kaushik A, Mahajan R, De D, et al. Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history Clin Exp Dermatol, 2020.PMID 32449205
10. [10]Chevalier K, Bader-Meunier B, Kone-Paut I, Terrier B, Hachulla E, Mouthon L, Chaigne B, Costedoat-Chalumeau N Juvenile-onset mixed connective tissue disease: A multicenter retrospective cohort study Semin Arthritis Rheum, 2026.PMID 41412094
11. [11]John KJ, Sadiq M, George T, et al. Clinical and Immunological Profile of Mixed Connective Tissue Disease and a Comparison of Four Diagnostic Criteria Int J Rheumatol, 2020.PMID 32411251
12. [12]Antoniou KM, Distler O, Gheorghiu AM, et al. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the European Task Force Ann Rheum Dis, 2026.PMID 40912974